ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: During the course of CML progression (chronic-, accelerated- and blast-crises phases), underlying gradual amplification of BCR-ABL-driven genomic instability and secondary modifications at genetic/epigenetic levels are believed to have major knock-on effect in altering and activating the expression of different mitogenic, anti-differentiating and anti-apoptotic modulators and mediators with resultant profound influence on the proteome profiles4, 5, 6.